Beyond Wrinkle Efficacy: Toward a Broader Assessment of Longitudinal Compatibility in Routine Upper-Face Aesthetic BoNT-A

Botulinum toxin A (BoNT-A) is well established for the esthetic treatment of upper-face dynamic lines, and long-term adult studies suggest that repeated treatment may remain effective and acceptable over time in many patients. However, wrinkle efficacy and patient satisfaction do not by themselves determine whether repeated treatment remains acceptable in broader morphologic, dynamic–expressive, and longitudinal terms. At the same time, the toxin’s pharmacology entails finite presynaptic blockade followed by active synaptic and architectural recovery, and imaging, histological, and neurophysiological studies indicate that repeated chemodenervation cannot be assumed to be biologically neutral at the muscle level. The resulting problem is not whether BoNT-A works, but whether current outcome frameworks are sufficient to judge repeated-treatment compatibility in full. Here, structural tolerance is proposed as a provisional clinical lens for an underdescribed boundary: whether repeated-treatment compatibility is fully captured by wrinkle reduction and patient acceptability alone. The paper organizes this problem across morphologic, dynamic–expressive, and longitudinal domains, outlines candidate warning signs, and develops a pragmatic tiered approach to assessment spanning routine care, structured clinical follow-up, and research-oriented evaluation. The aim is to support more complete longitudinal thinking in upper-face aesthetic BoNT-A, to clarify what current outcome frameworks remain unaddressed, and to identify priorities for future empirical study.